22nd Century Group (NASDAQ:XXII) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of 22nd Century Group (NASDAQ:XXII) in a research report report published on Monday. The firm issued a sell rating on the biotechnology company’s stock.

22nd Century Group Trading Down 17.4 %

XXII stock opened at $0.11 on Monday. The firm’s 50-day moving average is $0.34 and its two-hundred day moving average is $1.07. The company has a market capitalization of $900,511.20, a price-to-earnings ratio of 0.00 and a beta of 1.39. 22nd Century Group has a 52 week low of $0.10 and a 52 week high of $9.88.

22nd Century Group (NASDAQ:XXII) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. The firm had revenue of $7.95 million for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in 22nd Century Group stock. Anson Funds Management LP raised its holdings in 22nd Century Group, Inc. (NASDAQ:XXII) by 106.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,577,814 shares of the biotechnology company’s stock after acquiring an additional 3,399,323 shares during the quarter. Anson Funds Management LP owned 83.28% of 22nd Century Group worth $789,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 18.06% of the company’s stock.

About 22nd Century Group

22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.